Amwill Health Care Ltd
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies.[1]
- Market Cap ₹ 146 Cr.
- Current Price ₹ 72.9
- High / Low ₹ 105 / 64.5
- Stock P/E 13.6
- Book Value ₹ 34.6
- Dividend Yield 0.00 %
- ROCE 27.6 %
- ROE 24.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 46.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has high debtors of 150 days.
- Working capital days have increased from 75.4 days to 153 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 17 | 26 | 28 | 42 | 41 | |
| 18 | 22 | 24 | 25 | 29 | |
| Operating Profit | -1 | 4 | 4 | 17 | 12 |
| OPM % | -6% | 14% | 15% | 40% | 29% |
| 0 | -0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | 3 | 4 | 17 | 12 |
| Tax % | -3% | 23% | 25% | 25% | 10% |
| -1 | 3 | 3 | 13 | 11 | |
| EPS in Rs | -333.33 | 856.67 | 1,036.67 | 2,508.00 | 5.36 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| TTM: | -14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.05 | 20 |
| Reserves | -1 | 1 | 5 | 17 | 49 |
| 0 | 0 | 0 | 0 | 0 | |
| 9 | 5 | 8 | 2 | 2 | |
| Total Liabilities | 8 | 7 | 12 | 19 | 71 |
| 1 | 0 | 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 7 | 6 | 12 | 18 | 70 | |
| Total Assets | 8 | 7 | 12 | 19 | 71 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 3 | 5 | -3 | 6 | |
| -1 | -0 | -1 | -1 | -46 | |
| 0 | 0 | -0 | -0 | 41 | |
| Net Cash Flow | -1 | 3 | 3 | -4 | 1 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 93 | 12 | 16 | 114 | 150 |
| Inventory Days | 66 | 17 | |||
| Days Payable | 39 | 35 | |||
| Cash Conversion Cycle | 93 | 12 | 16 | 141 | 133 |
| Working Capital Days | -42 | -23 | -38 | 111 | 153 |
| ROCE % | 1,069% | 133% | 153% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16h - Amwill expands into 6 states, launches UVBREAK sunscreen, maintains ₹50Cr+ cash, debt-free status.
-
SUBMISSION OF STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED THROUGH INITIAL PUBLIC OFFER (''IPO")
29 May - No deviation in IPO fund utilization for quarter ended March 31, 2025.
- Audited Financial Results For The Half Year And Year Ended March 31, 2025. 29 May
-
Board Meeting Outcome for Board Meeting Intimation To Consider And Approve The Half Year And Yearly Audited Financial Results Of The Company For The Period Ended March 31St, 2025.
29 May - Audited FY25 results approved with unmodified opinion; ₹10 Cr invested in AAA+ mutual funds; IPO proceeds utilized as planned.
-
Board Meeting Intimation for Board Meeting Intimation For Audited Financial Results For Half Yeraly And Yearly For The Period Ened March 31, 2025 Of The Company.
26 May - Board meeting on May 29, 2025, to approve audited financial results for FY and H1 ended March 31, 2025.
Annual reports
No data available.
Business Overview[1]
Amwill Health Care Ltd is a derma-cosmetic company specializing in contract manufacturing, distribution, and third-party product development. It focuses on dermatological and aesthetic solutions, operating on an asset-light model by outsourcing manufacturing, testing, and distribution.